New developments for antibody-drug conjugate-based therapeutic approaches
Abstract
The clinical success of Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have...
Paper Details
Title
New developments for antibody-drug conjugate-based therapeutic approaches
Published Date
Jun 1, 2016
Volume
40
Pages
14 - 23
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History